LPCN earnings: real EPS beat/miss history, analyst consensus Buy, P/E -1.14. Updated 2026-07-23.
Lipocine (LPCN) Research Hub
Lipocine (LPCN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 2.27 USD (+0.89%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -1.14, market cap 0.01B. This hub links to the full technical, earnings and options research available for LPCN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.27 USD (+0.89%) |
| 52-week range | 2.04 USD – 2.61 USD |
| Trend regime | Range |
| 14-day RSI | 60 (Bullish) |
| Trailing P/E | -1.14 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
Available research for LPCN
Covered Call on LPCN: how it works, illustrative setup around the real 2.27 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on LPCN: how it works, illustrative setup around the real 2.27 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on LPCN: how it works, illustrative setup around the real 2.27 USD price, max profit/loss, breakeven and when to use it. Educational.
LPCN technical analysis: range, last 2.27 USD, RSI 60, 52w range 2.04 USD–2.61 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is LPCN in?
Lipocine (LPCN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is LPCN in an uptrend or downtrend?
As of 2026-09-11, LPCN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is LPCN's trailing P/E ratio?
LPCN's trailing P/E is -1.14, with a market cap of 0.01B. See the earnings research page for full valuation detail.